XML 22 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)
$ in Millions
 1 Months Ended
Jul. 31, 2019
USD ($)
program
May 31, 2019
USD ($)
Jan. 03, 2020
USD ($)
Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaboration agreement, number of programs | program 6    
Upfront payments $ 17.5    
Collaboration agreement pre-existing programs | program 3    
Preclinical development work on these programs $ 32.6    
Expense for the discovery and preclinical development funding commitment     $ 4.0
Maximum amount eligible for development and regulatory milestones 148.8    
Potential development and regulatory milestone payments 280.0    
Collaboration Agreement With Iconic Therapeutics, Inc.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expense for the discovery and preclinical development funding commitment     9.8
Collaboration agreement option exercise fee payment, upon exercising option     20.0
Maximum amount eligible for development and regulatory milestones     190.6
Potential development and regulatory milestone payments     $ 262.5
Upfront payment   $ 7.5  
Minimum | Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaboration agreement option exercise fee payment, upon exercising option 10.0    
Maximum | Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaboration agreement option exercise fee payment, upon exercising option $ 12.0